Abstract
Background: Recent advances in biologics have provided new insights into the clinical course of asthma, including disease modification and deep remission. However, to what extent can biologics achieve deep remission in patients with severe asthma is poorly documented.
Objective: To assess the achievement rate and predictictors of deep remission to biologics.
Methods: In this retrospective study, patients with severe asthma were included who initiated biologics (n=40). Patient backgrounds were collected at baseline and 1-year follow-up. "Deep remission" was defined as achievement of all five criteria, (1) ACQ score<1.5, (2) no asthma exacerbations, (3) no use of OCS, (4) %FEV1≥80%, (5) suppressed Type2 inflammation (B-Eos<300/μL and FeNO<50 ppb).
Results: 14 patients (35%) achieved deep remission. Compared to the group with non-deep remission, the group with deep remission had a higher frequency of adult-onset (92.9% vs. 66.4%, p=0.070), shorter duration of asthma (9 vs. 25 years, p=0.013), and higher %FEV1 (80.5% vs. 63.3%, p=0.005). There were no significant differences in ACQ, exacerbation frequency, or Type 2 inflammation at baseline between the two groups. The combination of asthma duration and %FEV1 could stratify the achievement rate of deep remission.
Conclusion: Our results suggest that the early introduction of biologics for patients with severe asthma could achieve deep remission.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4401.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
